CN117257790A - 芹菜素在制备用于治疗银屑病的药物中的应用 - Google Patents
芹菜素在制备用于治疗银屑病的药物中的应用 Download PDFInfo
- Publication number
- CN117257790A CN117257790A CN202311272058.7A CN202311272058A CN117257790A CN 117257790 A CN117257790 A CN 117257790A CN 202311272058 A CN202311272058 A CN 202311272058A CN 117257790 A CN117257790 A CN 117257790A
- Authority
- CN
- China
- Prior art keywords
- apigenin
- psoriasis
- ointment
- effect
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229940117893 apigenin Drugs 0.000 title claims abstract description 40
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 235000008714 apigenin Nutrition 0.000 title claims abstract description 40
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000002674 ointment Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 238000001647 drug administration Methods 0.000 abstract description 6
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 231100000321 erythema Toxicity 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000005259 measurement Methods 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 231100000915 pathological change Toxicity 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 239000006071 cream Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及生物医药技术领域，特别涉及芹菜素在制备用于治疗银屑病的药物中的应用。本发明通过制备芹菜素的药膏，在银屑病IMQ小鼠模型上验证药物效果，发现芹菜素的药膏能明显改善银屑病样的临床表现，对改善银屑病的鳞屑红斑状况、对减少角质层过度增殖有很好的效果。用药期间用药组的小鼠较病变组小鼠更为活泼，体重用药后无明显变化，表明药效安全可靠，无明显毒副作用。试验结果说明芹菜素制备的药膏有良好的缓解和治疗银屑病的效果。
Description
技术领域
本发明涉及生物医药技术领域，特别涉及芹菜素在制备用于治疗银屑病的药物中的应用。
背景技术
银屑病俗称牛皮癣，是一种慢性炎症性皮肤病。病程较长，有易复发倾向，有的病例几乎终生不愈。该病发病以青壮年为主，对患者的身体健康和精神状况影响较大。临床表现以红斑，鳞屑为主，全身均可发病。银屑病目前无法治愈，但医疗人员应通过在疾病过程的早期治疗患者、识别和预防相关的病症、逐步改变生活方式以及采用个性化的治疗方法，将患者的身体和心理伤害降至最低。
目前临床上治疗银屑病的方法分为外用治疗，口服治疗和生物免疫治疗，还有物理性治疗。外用药物治疗主要选择一些弱效的糖皮质激素，例如***乳膏，糠酸莫米松乳膏等，也可以选择一些钙调磷酸酶抑制剂，例如他克莫司乳膏，还可以选择一些维生素D3的衍生物，例如卡泊三醇乳膏。口服药物主要是维A类的药物，比如阿维A胶囊。生物免疫治疗主要指生物抗体类药物，如阿达木单抗，苏金单抗等。物理性的治疗方法是指局部的紫外线治疗和一些中药药浴治疗。
本发明通过动物实验证实了芹菜素对改善银屑病的鳞屑红斑状况、对减少角质层过度增生有显著的效果，为芹菜素在治疗银屑病的药物开发应用提供了扎实的基础。
发明内容
本发明通过试验结果说明芹菜素有良好的缓解和治疗银屑病的效果，为芹菜素在治疗银屑病的药物开发应用提供了扎实的基础。
本发明提供的技术方案为芹菜素在制备用于治疗银屑病的药物中的应用。
而且，所述药物的剂型为膏剂。
而且，膏剂的制备方法为将芹菜素水溶液加入到由硬脂酸、碳酸钾、单硬脂酸甘油酯、三乙醇胺、甘油和水制成的基质中，加热混匀即得。
而且，药物的给药方式为涂覆。
而且，芹菜素能替换为芹菜素的异构体、溶剂合物或前体，以及所述芹菜素的异构体、溶剂合物或前体的药学可接受盐。
与现有技术相比，该技术方案的有益效果在于：本发明通过制备芹菜素的药膏，在银屑病IMQ小鼠模型上验证药物效果，发现芹菜素的药膏能明显改善银屑病样的临床表现，对改善银屑病的鳞屑红斑状况、对减少角质层过度增殖有很好的效果。用药期间用药组的小鼠较病变组小鼠更为活泼，体重用药后无明显变化，表明药效安全可靠，无明显毒副作用。试验结果说明芹菜素制备的药膏有良好的缓解和治疗银屑病的效果。
附图说明
图1芹菜素药膏对小鼠银屑病样皮损改善情况；
图2芹菜素药膏对小鼠银屑病样表皮厚度改善情况；
其中，图1和图2中各组分别为Control:空白对照组；Model:银屑病模型组；Apigenin-H:芹菜素高剂量组(300mg/kg)；Apigenin-M:芹菜素中剂量组(150mg/kg)；Apigenin-L:芹菜素低剂量组(75mg/kg)；Calcipotriol：阳性药对照组(0.005％卡泊三醇乳膏50mg/次)。
图3为动物实验的流程图。
具体实施方式
下面结合附图和实施例对本发明进行详细具体说明，本发明的内容不局限于以下实施例。
实例一：芹菜素药膏的制备
称取1g的芹菜素溶于水中，加入到由硬脂酸3.67g，碳酸钾0.3g，单硬脂酸甘油酯0.83g，三乙醇胺0.1mL，甘油4mL，水适量制成的基质中，加热至70℃，混匀，即得。其中硬脂酸需单独预先加无水乙醇在70℃下助溶。
实例二：芹菜素药膏效果的试验
用C57BL/6Cnc雄性小鼠于背部区域2×3剃毛，恢复1天后，每天上午涂抹IMQ(咪喹莫特乳膏)建立银屑病IMQ模型小鼠，下午涂抹芹菜素药膏，同时给银屑病模型组小鼠涂抹空白基质。给药7天后，观察小鼠的背部皮肤损伤改善状况，发现给药组小鼠背部红斑、鳞屑明显少于银屑病模型组小鼠，皮肤明显光滑，且芹菜素药效具有明显的剂量依赖性。用药后体重无明显变化，而银屑病模型组小鼠体重明显下降。
综上，实验结果证明芹菜素具有制备用于治疗银屑病的药物的应用价值，且芹菜素药膏能明显改善银屑病的临床表现，药效安全显著，无明显毒副作用。
Claims (5)
1.芹菜素在制备用于治疗银屑病的药物中的应用。
2.根据权利要求1所述的芹菜素在制备用于治疗银屑病的药物中的应用，其特征在于：所述药物的剂型为膏剂。
3.根据权利要求2所述的芹菜素在制备用于治疗银屑病的药物中的应用，其特征在于：膏剂的制备方法为将芹菜素水溶液加入到由硬脂酸、碳酸钾、单硬脂酸甘油酯、三乙醇胺、甘油和水制成的基质中，加热混匀即得。
4.根据权利要求2所述的芹菜素在制备用于治疗银屑病的药物中的应用，其特征在于：药物的给药方式为涂覆。
5.根据权利要求1所述的芹菜素在制备用于治疗银屑病的药物中的应用，其特征在于：芹菜素能替换为芹菜素的异构体、溶剂合物或前体，以及所述芹菜素的异构体、溶剂合物或前体的药学可接受盐。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311272058.7A CN117257790A (zh) | 2023-09-28 | 2023-09-28 | 芹菜素在制备用于治疗银屑病的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311272058.7A CN117257790A (zh) | 2023-09-28 | 2023-09-28 | 芹菜素在制备用于治疗银屑病的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117257790A true CN117257790A (zh) | 2023-12-22 |
Family
ID=89217435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311272058.7A Pending CN117257790A (zh) | 2023-09-28 | 2023-09-28 | 芹菜素在制备用于治疗银屑病的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117257790A (zh) |
-
2023
- 2023-09-28 CN CN202311272058.7A patent/CN117257790A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016062283A1 (zh) | 抗发炎用药物在制备抑制癌症的医药组合物中的应用 | |
| EP3687513B1 (en) | Treatment of fragile x syndrome and autism with cannabidiol | |
| EP3666258B1 (en) | Method of treating prader-willi syndrome | |
| EP3821892A1 (en) | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds | |
| CN104039148A (zh) | 组合als疗法 | |
| JP2016509030A (ja) | ニトライトの医薬製剤及びそれらの使用 | |
| KR20200054171A (ko) | 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법 | |
| JP2019532112A (ja) | 結節性痒疹の治療方法 | |
| TW201247612A (en) | Compositions for treating kidney disorders | |
| KR20230031317A (ko) | 칸나비디올로의 취약 x 증후군의 치료 | |
| WO2014106473A1 (zh) | 甘草次酸、甘草酸在制备预防或治疗放射性软组织损伤药物中的应用 | |
| CN117257790A (zh) | 芹菜素在制备用于治疗银屑病的药物中的应用 | |
| CN116265017A (zh) | 一种包含本维莫德和皮质类固醇的药物组合物 | |
| KR20220157313A (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
| SE1350211A1 (sv) | Metoder och kompositioner för behandling av cancermetastaser | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
| CN110420209B (zh) | 一种治疗糖尿病周围神经痛的药物组合物及其应用 | |
| Egbu et al. | Steroid-induced hiccups in a patient managed for pseudo foster-kennedy syndrome: a case report of good outcome with the use of gabapentin | |
| Sapeika | Drugs in obesity | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| Muhammad | Hydrocortisone as Antiallergic Drug | |
| Hoang et al. | Zinc Iodide-Dimethyl Sulfoxide Composition in Treatment of Chronic Respiratory Diseases | |
| CN105338985A (zh) | 用于增加瘦素生成的比马前列素 | |
| CN117357528A (zh) | 一种激酶抑制剂的新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |